以“紫娟”普洱茶茶褐素为对象,研究“紫娟”普洱茶茶褐素对高脂饮食大鼠生长发育的影响。将实验大鼠分为正常对照组,高脂模型组,低、中、高剂量（即动物给药量0.135、0.405、1.215g/kg）茶褐素组及阳性对照组。观察“紫娟”普洱茶茶褐素对大鼠摄食量、饮水量、体质量、体长、肝脏指数的影响;通过电子显微镜观察茶褐素对实验大鼠肝脏病理变化的影响。结果表明：干预期结束后,“紫娟”普洱茶茶褐素对大鼠的进食、饮水、体长无影响;与高脂模型组相比,茶褐素组能抑制高脂饮食大鼠体质量的增长速度,不同程度地抑制了实验大鼠肝脏的脂变,减少肝脏脂肪沉积,具有预防实验动物脂肪肝形成的作用,中、高剂量茶褐素组效果尤为明显（P<0.5）。
The effect of theabrownin(TB) extracted from ‘Zijuan’ Pu-erh tea on growth of rats with hyperlipidemia food was studied. The experimental rats were divided into six groups: normal control group, positive control group, hyperlipidemia model group, and low-, medium-, and high-dose theabrownin treatment groups (0.135g/kg, 0.405g/kg, and 1.215g/kg body weight, respectively). The effect of theabrownin extracted from ‘Zijuan’ pu-erh tea on food intake, water intake, body weight and body length, index and pathology section of livers of rats was investigated. After the stage of intervention, TB showed no effect on food intake, water intake, and body length of rats. TB can significantly prevent the increasing of body weight and the fatty degeneration of rat livers with hyperlipidemia food. TB extracted from ‘Zijuan’ Pu-erh tea showed the effect on controlling body weight of hyperlipidemia rats, and it can decrease the fat deposition and prevent the formation of fatty livers of animals, especially with medium and high dose TB(P<0.5).
[1] 包云秀, 夏丽飞, 李友勇, 等. 茶树新品种“紫娟”[J]. 园艺学报, 2008, 35(6): 934.
[2] 梁名志, 夏涛. 特种紫茶降压活性物质初探[J]. 云南农业大学学报, 2003, 18(4): 378-381.
[3] 杨兴荣, 包云秀, 黄玫. 云南稀有茶树品“紫娟”的植物学特性和品质特征[J]. 茶叶, 2009, 35(1): 17-18.
[4] Wang QP, Peng CX, Gong JS.Effects of enzymatic action on the formation of theabrownin during solid state fermentation of Pu-erh tea[J]. J Sci Food Agric, 8 JUN, 2011, DOI: 10.1002/jsfa.4480.
[5] Gong JS, Peng CX, Chen T, et al. Effects of theabrownin from Pu-erh tea on the metabolism of serum lipids in rats: mechanism of action[J]. J Food Sci, 2010, 75(6): 182-189.
[6] 龚加顺, 陈文品, 周红杰, 等. 云南普洱茶特征成分的功能与毒理学评价[J]. 茶叶科学, 2007, 27(3): 287-289.
[7] 敬明武, 葛宇杰, 刘科亮. 茶色素胶囊对大鼠辅助调节血脂的研究[J]. 中国现代医生, 2007, 45(5): 18-19.
[8] 中华人民共和国卫生部. 保健食品检验与评价技术规范[M]. 2003: 2.
[9] 李运曼, 雷志冈, 杨贵成. 辛伐他汀与洛伐他汀的降血脂作用比较[J]. 中国药科大学学报, 2002, 33(5): 448-450.
[10] Kopelman PG.Obesity as medical problem[J]. Nature, 2000, 404: 635-643.
[11] Carek PJ, Dickerso LM.Current concepts in pharmacological management of obesity[J]. Drugs, 1999, 57(6): 883-904.
[12] 扬义生, 洪洁. 减肥药物的应用及研究现状[J]. 世界临床药物, 2003, 11: 654.
[13] 范建高, 曾民德, 王国良. 脂肪肝的发病机制[J]. 世界华人消化杂志, 1999, 7(1): 75-76.
[14] Chen J, Song W, Redinger R.Effects of dietary cholesterol on hepatic production of lipids and lipoproteins in isolated hamster liver[J]. Hepatology, 1996, 24: 424-431.
[15] Bachman AL, Dubin MD, Moukarzel AA.Choline deficiency, a cause of hepatic steatosis during parenteral nutrition that can be reverse with intravenous choline supplementation[J]. Hepatology, 1995, 22: 1399-1405.
浙公网安备 33019902000101号 
